Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:40:22.784Z.
Calculation as of: 2026-10-06T13:40:22.784Z.
Quote observation: 2026-10-06T13:39:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$115.66M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.67M
Price/OCF Ratio
N/A
TTM Avg
1.65
3Y Avg
1.65
5Y Avg
1.65
Market Cap
$118.52M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.31M
Price/OCF Ratio
N/A
TTM Avg
8.98
3Y Avg
8.98
5Y Avg
8.98
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $115.66M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A | 1.65 | 1.65 | 1.65 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.55M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $117.48M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $111.78M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $112.31M | N/A | 8.98 | 8.98 | 8.98 |
| Apyx Medical Corporation (APYX)vs › | $110.75M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
